ASCO/X
May 8, 2025, 10:41
Updated Guideline on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer – ASCO
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“We issued a guideline update on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
For men whose castration-sensitive prostate cancer was previously treated with systemic therapy, the type of that prior treatment will guide the selection of their next therapy for metastatic castration-resistant prostate cancer (mCRPC).
It’s recommended that androgen-deprivation therapy be continued without stopping for patients with mCRPC.
Read full article.”
More posts featuring American Society of Clinical Oncology on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 8, 2025, 13:09
May 8, 2025, 12:36
May 8, 2025, 11:36
May 8, 2025, 10:58